Pluristem Receives Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Germany

International Study Extends FDA Phase II Trial That Began in U.S.

Pluristem Therapeutics, Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-derived cell therapies, announced today that the Paul-Ehrlich-Institute (PEI), the medical regulatory body for biological medicinal products for the Federal Republic of Germany, has approved the company's request to initiate a Phase II study using PLX-PAD cells in patients suffering from Intermittent Claudication (IC). IC is a subset of Peripheral Artery Disease (PAD). According to The SAGE Group and HCUP 2007 Inpatient Data, the prevalence of IC in the United States is approximately 14 million patients, representing a cost of approximately $2.5 billion annually to the healthcare system.

Santarus Receives FDA Approval of UCERIS (Budesonide) for the Induction of Remission in Patients with Active, Mild to Moderate Ulcerative Colitis

Commercial launch expected in March 2013
Company provides 2013 financial guidance

Santarus, Inc. (SNTS) announced today that the U.S. Food and Drug Administration (FDA) has approved UCERIS^™ (budesonide) extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. The company expects to commence the commercial launch of UCERIS in March 2013.

U.S. Food and Drug Administration approves Cangene's VARIZIG®

Readers are referred to the cautionary notes regarding Forward-Looking Information at the end of this release.

Cangene Corporation ("Cangene") today announces that the United States Food and Drug Administration has approved VARIZIG^® [Varicella Zoster Immune Globulin (Human)] for post-exposure prophylaxis of varicella (chickenpox) in high risk patient groups including immunocompromised children, newborns and pregnant women.  VARIZIG is intended to reduce the severity of chickenpox infections in these patients.

Star Scientific, Inc./Rock Creek Pharmaceuticals Report Positive Initial Results of ASAP Human Thyroid Health Study Showing Benefits in Immune System Support

 Star Scientific, Inc. (STSI) announced today the preliminary results of the Company's ASAP (Anatabloc Supplementation Autoimmune Prevention) Human Thyroid Study that analyzes the impact of anatabine dietary supplementation on thyroid health. 

The study is a three-month, five-visit, double-blind, placebo-controlled study of the impact of anatabine dietary supplementation in humans with autoimmune disease of the thyroid.  The study was conducted at nine sites and builds upon previous epidemiological and animal experimental studies.  Initial results for all study subjects suggest that dietary supplementation with anatabine ameliorates the immune system's targeting of the thyroid gland in autoimmune thyroiditis.